---
title: "GIANT BIOGENE's subsidiary received the \"Medical Device Registration Certificate of the People's Republic of China\" for the recombinant Type I α1 subtype collagen freeze-dried fiber product"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/262346154.md"
description: "GIANT BIOGENE's wholly-owned subsidiary, Shaanxi Giant Biogene Technology Co., Ltd., has obtained the medical device registration certificate for recombinant type I α1 subtype collagen freeze-dried fiber products issued by the National Medical Products Administration of China. This is the first recombinant type I natural sequence collagen facial injection in China, marking the company's core competitiveness in technological research and development and industrialization, which will drive business development in the skin revitalization market in the future"
datetime: "2025-10-23T04:39:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262346154.md)
  - [en](https://longbridge.com/en/news/262346154.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262346154.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/262346154.md) | [繁體中文](https://longbridge.com/zh-HK/news/262346154.md)


# GIANT BIOGENE's subsidiary received the "Medical Device Registration Certificate of the People's Republic of China" for the recombinant Type I α1 subtype collagen freeze-dried fiber product

According to the Zhitong Finance APP, GIANT BIOGENE (02367) announced that its wholly-owned subsidiary, Shaanxi Giant Biogene Technology Co., Ltd., received the "Medical Device Registration Certificate of the People's Republic of China" (Registration Certificate No.: Guo Xie Zhu Zheng 20253132049) issued by the National Medical Products Administration of China today for its recombinant type I α1 collagen freeze-dried fiber product (the product). This product, which uses recombinant collagen as the main ingredient, is intended for facial dermal tissue filling to correct dynamic wrinkles on the forehead, including glabellar lines, forehead lines, and crow's feet.

This product is the first recombinant type I natural sequence collagen facial injection product approved in China, having passed the joint review of device and drug assessments. The approval of this product reflects the company's core competitiveness in technology research and development and industrialization, further enriching the company's product categories and bringing new opportunities for business development in the skin revitalization market. In the future, the company will gradually carry out the market promotion of this product according to its business plan and fully coordinate with existing products, brands, and channels to provide consumers with more diversified experiences, continuously consolidating the company's leading position in the health and beauty field

### 相关股票

- [GIANT BIOGENE (02367.HK)](https://longbridge.com/zh-CN/quote/02367.HK.md)

## 相关资讯与研究

- [Taizhou Water Group Signs New Connected Raw Water Supply Deal to 2028](https://longbridge.com/zh-CN/news/281542611.md)
- [PetroChina Renews Financial Deal With Related Company](https://longbridge.com/zh-CN/news/280998322.md)
- [10:23 ETInternational clinicians provide experience as new graduates join the workforce](https://longbridge.com/zh-CN/news/281541166.md)
- [Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe](https://longbridge.com/zh-CN/news/280997570.md)
- [EPC Space adds EPC7C010 and EPC7C011 half-bridge buck platforms for high-rel and rad-hard applications](https://longbridge.com/zh-CN/news/281400207.md)